Current and future assays for identifying recent HIV infections at the population level

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Smoleń Dzirba, Joanna ^a   Wasik, Tomasz J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Incidence; Recent HIV infection; Recent Infection Testing Algorithm (RITA); Serological Testing Algorithm for Recent HIV Seroconversion (STARHS); Surveillance

Indexed keywords

ALGORITHM; CLADISTICS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFECTION RATE; NONHUMAN; POPULATION RESEARCH; REVIEW; SEROLOGY; VIRAL GENETICS; VIRUS DETECTION;

EID: 79955942256     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881757     Document Type: Review

References (63)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/pdf/surveillance.pdf, last assessed: 20.03.2010
2. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint-Maurice: Institut de veille sanitaire, 2007; 75
3. Assays to estimate HIV incidence and detect acute HIV infection global landscape & market assessments (2009). Availaible at: http://www.who.int/diagnostics_laboratory/links/hiv_incidence_assay/en/index.html
4. Fisher M, Pao D, Murphy G et al: Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS, 2007; 21: 2309-14
5. WHO Technical Working Group on HIV incidence assays meeting report. 2009 July 16-17; Cape Town, South Africa. Final meeting report: 2009 Oct 5; Available at: http://www.who.int/diagnostics_laboratory/links/hiv_incidence_assay/en/index.html
6. Kuritzkes DR, Walker BD: HIV-1: Pathogenesis, clinical manifestations, and treatment. In: Knipe DM, Howley PM, ed. Fields Virology. 5th ed. Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins; 2007; 2187-214
7. Daar ES, Pilcher CD, Hecht FM: Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS, 2008; 3: 10-15
8. Parekh BS, McDougal JS: Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res, 2005; 121: 510-18
9. Development of assays to estimate HIV incidence: meeting proceedings (2009). Available at: http://www.fhi.org/en/RH/Pubs/booksReports/HIV_inc_assays.htm
10. Understanding HIV-1 incidence in Eastern and Southern Africa. A guidance note for policy makers, HIV programmers and HIV monitoring and evaluation practitioners (2009). Available at: http://www.unaidsrstesa.org/files/Incidence_june_09.pdf
11. Fiebig EW, Wright DJ, Rawal BD et al: Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS, 2003; 17(13): 1871-79
12. Pilcher CD, Fiscus SA, Nguyen TQ et al: Detection of acute infections during HIV testing in North Carolina. N Engl J Med, 2005; 352: 1873-83
13. Brookmeyer R, Quinn TC: Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol, 1995; 141(2): 166-72
14. Le Vu S, Pillonel J, Semaille C et al: Principles and uses of HIV incidence estimation from recent infection testing - a review. Euro Surveill. 2008;13(36): pii=18969. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18969
15. Janssen RS, Satten GA, Stramer SL et al: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA, 1998; 280: 42-48
16. Rawal BD, Degula A, Lebedeva L et al: Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr, 2003; 33: 349-55
17. Barin F, Meyer L, Lancar R et al: Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol, 2005; 43: 4441-47
18. Schüpbach J, Gebhardt MD, Tomasik Z et al: Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med, 2007; 4: 1921-30
19. Parekh BS, Kennedy MS, Dobbs T et al: Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses, 2002; 18: 295-307
20. Suligoi B, Galli C, Massi M et al: Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol, 2002; 40: 4015-20
21. Wilson KM, Johnson EIM, Croom HA et al: Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS, 2004; 18: 2253-59
22. Towler W, Khaki L, Wang L et al: Use of a high-resolution melting assay to evaluate HIV gag region diversity in HIV-infected adults with different stages of HIV infection. 17th Conference on Retroviruses and Opportunistic Infections; 2010, Feb 16-19; San Francisco, USA; 2010 (abstract no. 267)
23. Guy R, Gold J, Garcia Calleja JM et al: Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis, 2009; 9: 747-59
24. Murphy G, Parry JV: Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 2008;13(36): pii=18966. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18966
25. Withum DG, Janssen RS, Mei JV et al: Serological testing algorithm for recent HIV seroconversion (STARHS): CDC's investigational new drug program and uses of a testing strategy to detect early HIV-1 Infection. Int Conf AIDS, 2002 Jul 7-12; (abstract no. ThPeC7603)
26. Fiamma A, Lissouba P, Amy OE et al: Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial (ANRS-1265). BMC Infect Dis, 2010; 10: 137
27. Palella FJ Jr, Deloria-Knoll M, Chmiel JS et al: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med, 2003; 138: 620-26
28. Grant RM, Hecht FM, Warmerdam M et al: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA, 2002; 288(2): 181-88
29. Editorial team: Workshop on the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) and HIV Incidence Estimates, Stockholm, 11-12 March 2008. Euro Surveill. 2008;13(36): pii=18972. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18972
30. Kothe D, Byers RH, Caudill SP et al: Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr, 2003; 33: 625-34
31. Sill AM, Kreisel K, Deeds BG et al: Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infections. J Clin Lab Anal, 2007; 21: 40-45
32. Soroka SD, Granade TC, Candal D, Parekh BS: Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diag Lab Immunol, 2005; 12: 918-21
33. Kshatriya R, Cachafeiro AA, Kerr RJ et al: Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol, 2008; 46: 3482-83
34. Constantine NT, Sill AM, Jack N et al: Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less sensitive test strategy. J Acquir Immune Defic Syndr, 2003; 32: 94-103
35. Li H, Ketema F, Sill AM et al: A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection. Int J Infect Dis, 2007; 11: 459-65
36. Young CL, Hu DJ, Byers R et al: Evaluation of a sensitive/less sensitive testing algorithm using the bioMérieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses, 2003; 19: 481-86
37. Withum DG, Janssen RS, Mei JV et al: Serological testing algorithm for recent HIV seroconversion (STARHS) investigational new drug program for a testing strategy to detect early HIV-1 infection. Int Conf AIDS; 2000 Jul 9-14; (abstract no. MoOrA109)
38. Laeyendecker O, Rothman RE, Henson C et al: The effect of viral suppression on cross sectional incidence testing in the Johns Hopkins hospital emergency department. J Acquir Immune Defic Syndr, 2008; 48: 211-15
39. Barin F, Nardone A: Monitoring HIV epidemiology using assays for recent infection: where are we? Euro Surveill. 2008;13(36): pii=18967. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18967
40. Martro E, Suligoi B, Gonzalez V et al: Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J Clin Microbiol, 2005; 43: 6197-99
41. Suligoi B, Massi M, Galli C et al: Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr, 2003; 32: 424-28
42. Adonsu-Hoyi Y, Calder-Kent B, Malloch L et al: Examination of avidity in STARHS testing for HIV incidence. STARHS Workshop in association with the 16th International Conference on AIDS; 2006 Aug 13-18; Toronto, Canada; 2006
43. Chawla A, Murphy G, Donnelly C et al: Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol, 2007; 45: 415-20
44. Wei X, Liu X, Dobbs T et al: Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses, 2010; 26: 61-71
45. Selleri M, Orchi N, Zaniratti MS et al: Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr, 2007; 46: 145-50
46. Suligoi B, Butto S, Galli C et al: Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol, 2008; 41: 288-92
47. Calypte Biomedical Corporation. Product insert for: Aware™ BED™ EIA HIV-1 Incidence Test (IgG-Capture HIV-EIA). Enzyme immunoassay for population estimates of EIA HIV-1 Incidence. 2008
48. Dobbs T, Kennedy S, Pau CP et al: Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol, 2004; 42(6): 2623-28
49. UNAIDS Reference Group on Estimates, Modelling and Projections. Statement on the use of the BED-assay for the estimation of HIV-1 incidence for surveillance or epidemic monitoring. Available at: http://data.unaids.org/pub/EPISlides/2006/Statement_BED_Policy_13Dec05_en.pdf, last assessed: 25.06.2010
50. Karita E, Price M, Hunter E et al: Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS, 2007; 21(4): 403-8
51. Gupta SB, Murphy G, Koenig E et al: Comparison of methods to detect recent HIV type 1 infection in cross-sectionally collected specimens from a cohort of female sex workers in the Dominican Republic. AIDS Res Hum Retroviruses, 2007; 23: 1475-80
52. Hayashida T, Gatanaga H, Tanuma J, Oka S: Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses, 2008; 24(3): 495-98
53. Marinda ET, Hargrove JW, Preiser W et al: Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr, 2010; 53(4): 496-99
54. Hall IH, Song R, Rhodes P et al: Estimation of HIV incidence in the United States. JAMA, 2008; 300(5): 520-29
55. Hargrove JW, Jean H. Humphrey JH, Mutasa K et al: Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS, 2008; 22: 511-18
56. Parekh B: Calibration, validation and application of the BED assay for recent HIV-1 infection in multiple subtypes. Conference on HIV Diagnostics: New Developments and Challenges; 2005 Feb 28-Mar 1; Florida, USA; 2005
57. Kim AA, McDougal JS, Hargrove J et al: Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in Sub-Saharan Africa. AIDS Res Hum Retroviruses, 2010; 26(10): 1051-61
58. Le Vu S, Le Strat Y, Cazein F et al: Population-based HIV incidence in France, 2003 to 2008. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco, USA; 2010 (abstract no. 36LB)
59. Sakarovitch C, Rouet F, Murphy G et al: Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr, 2007; 45: 115-22
60. Semaille C, Cazein F, Pillonel J et al: Four years of surveillance of recent HIV infections at country level, France, mid 2003-2006: Experience and perspectives. Euro Surveill. 2008;13(36): pii=18968. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18968
61. Curtis KA, Kennedy S, Delaney K et al: IgG3 as a biomarker for distinguishing recent from established HIV-1 infection. 2010 HIV Diagnostics Conference; 2010 March 24-26; Orlando, USA; 2010
62. Laeyendecker O: Session II: Measuring new HIV infections; where we are with new technologies and approaches measuring HIV incidence. BED + avidity testing algorithm for incidence estimates in Uganda. The 2nd Global HIV/AIDS Surveillance Meeting. Bangkok, Thailand, 2009. Available at: http://www.hivsurveillance2009.org/docs/session_ii/pres4.ppt
63. Novitsky V, Wang R; Kebaabetswe L et al: Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1 C infection. J Acquir Immune Defic Syndr, 2009; 52(2): 265-72